Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Joyzyme Group's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.01.
Joyzyme Group's long-term debt to total assets ratio
increased
from Dec. 2024 (0.00) to Dec. 2025 (0.01).
It may suggest that Joyzyme Group is progressively becoming more dependent on debt to grow their business.
Joyzyme Group (HKSE:08622) LT-Debt-to-Total-Asset Explanation
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Joyzyme Group LT-Debt-to-Total-Asset Related Terms
Joyzyme Group LT-Debt-to-Total-Asset Historical Data
* Premium members only.
The historical data trend for Joyzyme Group's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joyzyme Group (HKSE:08622) has a LT-Debt-to-Total-Asset of 0.01 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Joyzyme Group and its competitors.
Is Joyzyme Group's LT-Debt-to-Total-Asset too high?
Joyzyme Group's current LT-Debt-to-Total-Asset is 0.01. Overall, Joyzyme Group has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Joyzyme Group's LT-Debt-to-Total-Asset compare to ZTS?
Joyzyme Group's LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Joyzyme Group and its competitors. Joyzyme Group's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joyzyme Group stock overvalued right now?
Based on GuruFocus' analysis, Joyzyme Group (HKSE:08622) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.17, compared to a current price of HK$0.17 — trading 2.9% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. Joyzyme Group's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Joyzyme Group (HKSE:08622), the current LT-Debt-to-Total-Asset is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joyzyme Group (HKSE:08622) Overvalued in 2026?
Based on GuruFocus' analysis, Joyzyme Group stock appears to be undervalued.
The current stock price of HK$0.17 is trading 2.9% below its estimated GF Value™ of HK$0.17.
GuruFocus considers Joyzyme Group to be Fairly Valued.
Key valuation signals for HKSE:08622:
LT-Debt-to-Total-Asset: 0.01
GF Value™: HK$0.17 vs. price of HK$0.17 (2.9% below fair value)
No single metric tells the full story. See the HKSE:08622 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressNo.16 Yinkui Road, 1-3 floor and 5th floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN
Joyzyme Group Ltd is an investment holding company. The Company and its subsidiaries are principally engaged in research and development, manufacture, marketing, and sale of biological reagents and auxiliary reproductive supplies and equipment, and healthcare products and supplements in the People's Republic of China (the PRC). It operates in two segments: Biological reagents and auxiliary reproductive supplies and equipment, and Healthcare products and supplements. It generates the majority of its revenue from the biological reagents and auxiliary reproductive supplies and equipment segment. Geographically, it generates revenue from the PRC.
40GF Score
Get the complete analysis for HKSE:08622
LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08622 has been successfully added to your 
